Article Sidebar
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Evaluation of potential cytotoxic and apoptotic effects of bioymifi on human multiple myeloma cell lines
Abstract
Purpose: To investigate the cytotoxic and apoptotic activities of bioymifi (DR5 agonist) on bortezomibsensitive and bortezomib-resistant cells.
Methods: The cytotoxic activities of bioymifi against bortezomib-sensitive (U266) and bortezomibresistant (U266/BR) cells were evaluated using XTT cell viability test. The cells were exposed to increasing concentrations of bioymifi for 24 h. Cell cycle analysis was performed while apoptosis was examined by flow cytometry.
Results: Bioymifi showed significant cytotoxic effects on U266 and U266/BR in a concentrationdependent manner (p < 0.05). The IC50 values of bioymifi in U266 and U266/BR cells were 10.4 and 20.9 µM, respectively. Moreover, when compared to the untreated cells, bioymifi treatment at IC50 concentrations considerably increased the percentage of apoptotic cells. Bioymifi treatment also caused cell cycle arrest at the G2/M phase in both cell types.
Conclusion: The results show that bioymifi is a promising candidate for multiple myeloma treatment. However, further studies are required to evaluate the clinical anticancer activity of this agent.
